ClinicalTrials.gg
RecruitingNCT06910241Updated Jan 7, 2026

Lidocaine Versus Diphenhydramine to Achieve Local Anesthesia for Laceration Repairs

A Phase 3 interventional study of Lidocaine and Diphenhydramine in Laceration of Skin, sponsored by Florida Atlantic University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Florida Atlantic University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Lacerations with a site in United States — 12 open to participants now, 14 under way, 1 of them phase 3. Lacerations · United States.

Planned enrollment
11th of 52
100 · median 52
Started
2025
with 3 others
Phase 3
Only one
of the 60
Primary completion
2027-06
later than 5 of 13 live
Registered
52nd of 60
by date

Among the 60 studies in Lacerations with a site in United States, this one is the 11th largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2025, is the only one in phase 3, reaches primary completion later than 5 of the 13 other live ones, and was the 52nd registered.

Lacerations

174 studies on the registry are indexed under Lacerations; 42 are open to participants now.

Browse Lacerations studies →

Open to participants now

12 of the 60 studies in Lacerations with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Lacerations studies recruiting now, 14 (54%) set no upper age limit and 10 (38%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Lacerations with a site in United States, or all of them as a file.
02

Study summary

Diphenhydramine, when injected locally, has been shown to achieve a certain level of local anesthesia. It has been documented for use in simple bedside procedures, however there is a gap in knowledge in its comparison to lidocaine. The purpose of the study is to determine if local infiltration of diphenhydramine is noninferior to the use of lidocaine 1% when trying to achieve local anesthesia for simple laceration repair. Patients who present to the emergency department with a simple laceration will be enrolled in the study. Patients will be evaluated for the pain of the injection as well as the pain of the laceration repair procedure post injection.

03

Conditions studied

  • Laceration of Skin

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lacerations requiring one layer of sutures
  • Lacerations appropriate for repair by emergency physicians

Exclusion criteria

Exclusion Criteria:

  • Active bleeding from laceration
  • Complex lacerations requiring multiple layers
  • Lacerations to be repaired by a specialist service
  • Patients with allergies to either diphenhydramine or lidocaine
  • Laceration repairs would benefit from the use of epinephrine as an additive to the local anesthetic
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Lidocaine

    Drug: Lidocaine

  • Experimental
    Diphenhydramine

    Drug: Diphenhydramine

Interventions

06

What researchers measure

Primary outcomes

  1. Sensation reduction

    Participants will rate their sensation level on a visual analog scale from 0 to 10 both before the drug injection and after the laceration repair procedure. 0 indicating no sensation and 10 indicating worst sensation. Reduction in sensation will be calculated as the difference between the pre-injection and post-procedure sensation, with a larger number indicating a greater reduction in sensation.

    Time frame: Measurements will be recorded before drug injection and immediately after laceration repair.

Secondary outcomes

  1. Anesthesia satisfaction by patient

    Patient satisfaction of anesthesia yes/no

    Time frame: Immediately after laceration repair

  2. Anesthesia satisfaction by physician

    Physician satisfaction of anesthesia yes/no

    Time frame: Immediately after laceration repair

07

Study locations

1 of 1 sites recruiting
  • Bethesda Hospital East
    Boynton Beach, Florida 33435, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 4, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06910241
Lead sponsor
Florida Atlantic University
Collaborators
Baptist Health South Florida
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Sep 3, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jan 7, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphenhydramine

Start the discussion